A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

This study is looking for adults aged 60 or older who have Mantle Cell Lymphoma that hasn't been treated before. If you're aged 60 to under 70, you'd only be considered if you have other health issues that prevent you from having a stem cell transplant. You also need to have lymphoma that can be measured, for example, on a scan, and you should generally feel well enough to participate.

There are also some reasons why you might not be able to join the study. For instance, if your lymphoma has spread to your brain or spinal cord, or if you have severe heart problems or a significant bleeding disorder. You also can't be in the study if you have active infections or if you need certain medications that could interfere with the study drugs. The treatment goal must also be to treat your lymphoma as a main therapy, not just to reduce it before a stem cell transplant.

The research team will review your full medical history to confirm if this study is suitable for you. This ensures your safety and that the study is right for your specific situation.

If you decide to join this study, you will be randomly assigned to one of two treatment groups, like flipping a coin. This means neither you nor your doctor can choose which drug combination you receive. You will receive either zanubrutinib plus rituximab or bendamustine plus rituximab. The treatments will involve taking medication, likely in cycles, with regular visits to the clinic for check-ups, blood tests, and scans to see how you're responding to the treatment and to monitor for any side effects. You will be closely monitored throughout the study. The total duration of your participation, including regular follow-up after your main treatment, will be explained by the study team.